Company Information
Industry 制造业
Company Introduction 河南新天地药业股份有限公司位于河南省长葛经济技术开发区,成立于2005年,注册资金1亿元。主要从事医药中间体和原料药的研发、生产与销售,是全球重要的阿莫西林合成侧链——左旋对羟基苯甘氨酸生产企业,牵头或参与制定了左旋对羟基苯甘氨酸、对甲苯磺酸及左旋对羟基苯甘氨酸甲酯等多个产品的行业标准,是河南省第二批专精特新企业。 公司拥有多项核心技术发明专利,其中1项同时获美、英、日、印等8个国家发明授权。公司始终坚持走绿色发展和高质量发展道路,2019年下半年,在河南省17个行业绿色发展调研评比中,公司位居医药行业第一名;2020年,公司举办了河南省双重预防现场观摩会;2021年,公司取得重污染天气重点行业绩效A级评级。 公司先后荣获河南省专精特新企业、河南省技术创新示范企业、河南省节能减排科技创新示范企业、河南省知识产权示范企业等多项荣誉和资质。 公司总部在河南省长葛市,地处中国的中心部位,地理位置优越,投资环境优良,自然资源及人力资源丰富。长葛市交通及通迅条件便利,京广铁路,京广客运专线(高铁),郑州-机场-许昌城市轻轨,京港澳高速及107国道穿市而过,南临古都许昌市(20公里),北靠省会郑州市(60公里),距郑州新郑国际机场30公里。
Main Business 主要从事手性医药中间体的研发、生产和销售。
Legal Representative 谢建中
Top Executives
董事长:谢建中
副董事长:刘万民
董事:刘宏民,刘超,张丙刚,张芦苇
独立董事:可钰,贾发亮,王京宝
Top 5 Shareholder
Shareholder name Nature Holding Date
河南双洎实业有限公司限售股63.21%30/09/2024
长葛市中远商贸有限公司限售股11.02%30/09/2024
李金登限售股+流通A股0.68%30/09/2024
陈培东流通A股0.35%30/09/2024
刘珍宝流通A股0.25%30/09/2024
Company Secretary 吴彦资
Solicitors 北京市竞天公诚律师事务所
Auditors 毕马威华振会计师事务所(特殊普通合伙)
Tel No 0374-6103777
Fax No 0374-6105968
Website www.newlandpharma.com
Email board@hnnewland.com
Company Address
Register: 河南省许昌市长葛市魏武路南段东侧
Office: 河南省许昌市长葛市魏武路南段东侧
Listing Date 16/11/2022
Shares Capital
Shares Capital: 280,056,000
Total A Share: 280,056,000
Listed A Share: 72,156,000
Non-tradable A Share: 207,900,000
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.790
DPS(RMB)* ¥ 0.400
NBV Per Share(RMB)* ¥ 7.239
Market Capitalization(RMB) 1.131B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.